http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6290951-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9089461ee71353d9df911820ff129558
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 1998-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8509b93457a0372a3043f1b93f4d77a
publicationDate 2001-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-6290951-B1
titleOfInvention Alteration of the cell cycle in vivo, and particularly for inducing apoptosis of tumor cells
abstract A first substance (such as the peptide aldehydes LLnL and LVP) inhibits the function of intracellular proteasome. A second substance (such as ranpirnase) inhibits intracellular protein synthesis or increases intracellular expression of a cyclin-dependent kinase (CDK) inhibitor. Both substances are administered in such a manner that the effects thereof are coincident. The cell cycle of affected tumor cells is therefore arrested and the cells die of apoptosis.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8846030-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11702672-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005037497-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006093585-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008249050-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11684679-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7749491-B2
priorityDate 1998-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5559212-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID231990137
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129387883
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129139972
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226583483
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227861700
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443118
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228296471
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID455779
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644345
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127468556
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID121855
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127870399

Total number of triples: 41.